Funder
This study was funded by Novartis (Taiwan) Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference33 articles.
1. World Alzheimer Report 2019. Alzheimer’s disease international: attitudes to dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf. Accessed 16 Dec 2019.
2. Wang WF, Chiu PY, Lin YT, Hu CJ, Fuh JL, Yang YH. Registration of Alzheimer’s disease in Taiwan: patient and informant. Am J Alzheimers Dis Other Demen. 2014;29:18–22.
3. Fan LY, Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, et al. Marital status, lifestyle and dementia: a nationwide survey in Taiwan. PLoS ONE. 2015;10: e0139154.
4. Chang CC, Peng GS, Lai TJ, Li CH, Liu CK. A 48-week, multicenter, open-label, observational study evaluating oral rivastigmine in patients with mild-to-moderate Alzheimer’s disease in Taiwan. Adv Ther. 2019;36:1455–64.
5. Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-22.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献